About Caribou Biosciences
Caribou Biosciences (NASDAQ:CRBU) is a biotechnology company focused on revolutionizing healthcare through the development of CRISPR-based technology platforms for genome editing. With a strong commitment to innovation, Caribou is actively pursuing a diverse range of projects aimed at developing therapeutic treatments that can address unmet medical needs across various diseases. The company is at the forefront of utilizing CRISPR-Cas systems to engineer cell therapies with the potential to deliver life-changing benefits to patients. As part of its objectives, Caribou is dedicated to advancing its pipeline of products through rigorous scientific research, while upholding the highest standards of quality and ethical considerations in gene editing.
Snapshot
Operations
Products and/or services of Caribou Biosciences
- CRISPR-Cas genome editing technology for developing advanced cell therapies.
- Allogeneic CAR-T cell therapies targeting hematologic cancers.
- CB-010, the lead allogeneic CAR-T cell therapy for B cell malignancies.
- In vivo gene editing programs for various genetic diseases.
- Next-generation CRISPR technologies for enhanced precision and efficiency.
- Collaborations with pharmaceutical companies to utilize CRISPR for drug discovery and development.
Caribou Biosciences executive team
- Dr. Rachel E. Haurwitz Ph.D.Co-Founder, CEO, President & Director
- Mr. Timothy P. Kelly M.B.A.Chief Technology Officer
- Ms. Barbara G. McClung Esq., J.D.Chief Legal Officer & Corporate Secretary
- Mr. Sriram Ryali M.B.A.Chief Financial Officer
- Mr. Daniel PoonVice President of Operations & Information Technology
- Mr. Ryan FischesserInterim Principal Accounting Officer & Controller
- Ms. Amy Figueroa C.F.A.Vice President of Investor Relations & Corporate Communications
- Ms. Reigin ZawadzkiChief People Officer
- Ms. Ruhi A. Khan M.B.A.Chief Business Officer
- Dr. Tina Albertson M.D., Ph.D.Chief Medical Officer